Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) the regenerative medical devices company today announces subsidiary CellRight Technologies (“CellRight”) has signed a long-term, multi-year distribution agreement with Arthrex, Inc., a premier innovator of orthopaedic surgical solutions.

CellRight, which produces industry leading verified osteobiologics for use in orthopaedic, spine and foot and ankle procedures, enhances the healing opportunities of defects caused by trauma and disease.

The multi-year commitment will give surgeons access to verified osteobiologics and advanced surgical instrumentation and techniques to help influence better patient outcomes.

Jesus Hernandez, CEO for CellRight Technologies comments on the long-term agreement:  “This long-term distribution agreement will allow physicans and patients better access to CellRight’s innovative orthobiologics through the Arthrex network. Our shared vision of offering surgeons total solutions which can positively impact patient outcomes solidifies the decision of both companies to work together.”

Steve Couldwell, CEO Tissue Regenix Group plc also commented: “This is a flagship distribution agreement for CellRight and the wider Tissue Regenix Group. It highlights the value of strategic partnerships with prestigious companies in this space. We look forward to working with Arthrex to bring the CellRight product portfolio to an extended network of healthcare professionals.”